Thyroid cancer is the most common endocrine malignancy, and thyroid carcinoma (PTC) has the highest incidence rate, accounts for about 85%~90% of thyroid carcinoma. There are many markers of PTC, such as murine sarcoma viral oncogene homolog B1 (BRAF), telomerase reverse transcriptase, Ki-67, microRNA-146b, PDZ and LIM domain 5 (PDLIM5). Among them, BRAF plays an important role in the carcinogenesis, development and prognosis of PTC. This article summarizes the research progress of BRAF signaling pathway, its role in the carcinogenesis, development and prognosis of PTC, its clinical correlation with the clinical pathological characteristics of PTC, and its application in the diagnosis and treatment of PTC to provide the references to readers.
甲状腺癌是最常见的内分泌恶性肿瘤，其中甲状腺乳头状癌(PTC)的发病率最高，约占甲状腺癌的85%～90%。有关PTC的肿瘤标志物很多，如鼠类肉瘤滤过性毒菌致癌同源体B1(BRAF)、端粒酶逆转录酶、Ki-67、微小RNA146b、PDLIM5等，其中BRAF基因在PTC的发生、发展和预后中发挥重要的作用。文章总结了BRAF基因及其信号通路、BRAF基因在PTC发生发展和预后中的作用、BRAF基因与PTC临床病理特征的相关性、BRAF基因在PTC诊断和治疗中的研究进展等，以供读者参考。.
Keywords: Diagnosis; Murine sarcoma viral oncogene homolog B1; Thyroid papillary carcinoma; Treatment.